[HTML][HTML] Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy
H Wang, H Zhou, J Xu, Y Lu, X Ji, Y Yao, H Chao… - Cancer Letters, 2021 - Elsevier
Cancer Letters, 2021•Elsevier
Glioblastoma multiforme (GBM) is a brain tumor with a high mortality rate. Surgical resection
combined with radiotherapy and chemotherapy is the standard treatment for GBM patients,
but the 5-year survival rate of patients despite this treatment is low. Immunotherapy has
attracted increasing attention in recent years. As the pioneer and the main effector cells of
immunotherapy, T cells play a key role in tumor immunotherapy. However, the T cells in
GBM microenvironment are inhibited by the highly immunosuppressive environment of …
combined with radiotherapy and chemotherapy is the standard treatment for GBM patients,
but the 5-year survival rate of patients despite this treatment is low. Immunotherapy has
attracted increasing attention in recent years. As the pioneer and the main effector cells of
immunotherapy, T cells play a key role in tumor immunotherapy. However, the T cells in
GBM microenvironment are inhibited by the highly immunosuppressive environment of …
Abstract
Glioblastoma multiforme (GBM) is a brain tumor with a high mortality rate. Surgical resection combined with radiotherapy and chemotherapy is the standard treatment for GBM patients, but the 5-year survival rate of patients despite this treatment is low. Immunotherapy has attracted increasing attention in recent years. As the pioneer and the main effector cells of immunotherapy, T cells play a key role in tumor immunotherapy. However, the T cells in GBM microenvironment are inhibited by the highly immunosuppressive environment of GBM, posing huge challenges to T cell-based GBM immunotherapy. This review summarizes the effects of the GBM microenvironment on the infiltration and function of different T-cell subsets and the possible strategies to overcome immunosuppression, and thus enhance the effectiveness of GBM immunotherapy.
Elsevier
